Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study

BMC Public Health

Jing Zhao²  Hongmin Wu²  Lei Zhang¹  Na Chen¹  Ning Zhang¹  Jiaxi Yu¹  Pan Zhang¹  Peipei Chen¹  Yanan Zhu²  Peian Lou¹ 

[1] Xuzhou Center for Disease Control and Prevention, 142 West Erhuan Road, Xuzhou City, Xuzhou 221006, Jiangsu Province, People's Republic of China;Department of Respiratory Medicine, Affiliated Hospital of Xuzhou Medical College, 99 West Huaiai Road, Xuzhou City, 221006, Jiangsu Province, People's Republic of China

关键词: Economic burden;    Treatments;    Beliefs;    Vulnerability;    COPD;   

Others  :  1163688
DOI  :  10.1186/1471-2458-12-287

 received in 2011-09-18, accepted in 2012-04-13,  发布年份 2012

【 摘 要 】

Background

The incidence of chronic obstructive pulmonary disease (COPD) in China is very high. This study aimed to assess the vulnerability of COPD patients in rural areas outside Xuzhou City, Jiangsu province, in order to provide helpful guidance for future research and public policies.

Methods

The vulnerability of 8,217 COPD patients was evaluated using a face-to-face questionnaire to obtain information on general characteristics, awareness, beliefs, medication usage, acute exacerbation of the disease, and economic burdens. Direct economic burdens were calculated based on the questionnaire, and indirect economic burdens were estimated using local per capita income and life expectancy in 2008. The years of potential life lost were calculated using loss of life years for each age group and multiplying by the number of deaths in a given age group.

Results

Of the 8,217 patients, 7,921 (96.4%) had not heard of COPD, and 2,638 (32.1%) did not understand that smoking was a risk factor for COPD. No patients had used inhalers, nebulizer drugs or oxygen therapy, either regularly or sporadically. No patients had undergone pulmonary rehabilitation or surgical treatment, while 4,215 (51.3%) took theophylline to relieve dyspnea, and 3,418 (41.6%) used antibiotics to treat exacerbations. A total of 2,925 (35.6%) patients had been admitted to hospital during the past year because of respiratory symptoms. The average direct and indirect economic burdens on COPD patients were 1,090 and 20,605 yuan, respectively.

Conclusions

The vulnerability of patients in rural Xuzhou to COPD was high. Their awareness of COPD was poor, their treatment during both the stable and acute exacerbation stages did not meet standards, and the economic burdens were large. Interventions are therefore needed to improve the prevention and management of COPD in this population. Further studies are required to verify these findings.

【 授权许可】

   
2012 Lou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2010. Available from: http://www.goldcopd.org/guidelines-global-strategyfor-diagnosis-management.html. Accessed August 23, 2011.
• [2]Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S: Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006, 27(2):397-412.
• [3]Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3(11):e442.
• [4]World Health Organization: World Health Statistics 2008. Geneva: World Health Organization 2008.
• [5]Chan-Yeung M, Aït-Khaled N, White N, Ip MS, Tan WC: The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis 2004, 8(1):2-14.
• [6]Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, Liu S, Wang X, Wang D, Lu J, Zheng J, Ran P: Prevalence of chronic obstructive pulmonary disease in China—a large population based spirometry based cross-sectional survey. Am J Respir Crit Care Med 2007, 176(8):753-760.
• [7]Fang XC, Wang XD, Bai CX: Burden and importance of proper management about chronic obstructive pulmonary disease in China. Int J Respir 2011, 31(7):493-497.
• [8]Bakerly ND, Davies C, Dyer M, Dhillon P: Cost analysis of an integrated care model in the management of acute exacerbations of chronic obstructive pulmonary disease. Chron Respir Dis 2009, 6(4):201-208.
• [9]Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946.
• [10]National Collaborating Centre for Chronic Conditions: Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004, 59(Suppl 1):1-232.
• [11]Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, Partridge MR: Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006, 130(1):133-142.
• [12]Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J: Impact of COPD in North America and Europe in 2000:subjects’perspective of confronting COPD international survey. Eur Respir J 2002, 20(4):799-805.
• [13]Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA: Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 169(12):1298-1303.
• [14]Ulrik CS, Hansen EF, Jensen MS, Rasmussen FV, Dollerup J, Hansen G, Andersen KK, KVASIMODO II study group: Management of COPD in general practice in Denmark – participating in an educational program substantially improves adherence to guidelines. Int J Chron Obstruct Pulmon Dis 2010, 5:73-79.
• [15]Chen YH, Yao WZ, Kang J, Cai BQ, Zhou X, Liu Z, Chen P, Sun DJ, Zheng JP, Wang GY, Feng YL, Xu YJ, Jia Y, Lu M, Chang C, Wang XH: Attitudes and actions of chronic obstructive pulmonary disease patients on treatment:a national multi-center investigative study. Chin J Tubec Respir Dis 2010, 33(10):750-753.
• [16]Chai JJ, Liu T, Cai BQ: Evaluation of clinical significance of chronic obstructive pulmonary disease assessment test. Chin J Tubec Respir Dis 2011, 34(4):256-258.
• [17]Fan CF, Yang YF, Cao GW: Application of vulnerability appraising in constructing theoretical model for early warning of emergent public health event. Acad J Sec Mil Med Univ 2007, 28(10):116-119.
• [18]Chen JC, Wang AM, Wang F: Public Health Emergency Response Mechanism and Assessment System. [J] China Inspection and Quarantine 2007, 20(02):25-26.
• [19]Chinese Society of Respiratory Disease, chronic obstructive pulmonary disease group: Diagnosis and treatment guidelines of chronic obstructive pulmonary disease(revised edition in 2007). Chin J Intern Med 2007, 46:254-261.
• [20]Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Grit Care Med 2001, 163(5):1256-1276.
• [21]Jones PW: Quality of life measurement for patients with disease of the airways. Thorax 1991, 46(9):676-682.
• [22]Partridge MR, van der Molen T, Myrseth SE, Busse WW: Attitudes and actions of asthma patients on regular maintenance therapy:the INSPIRE study. BMC Pulm Med 2006, 6:13. BioMed Central Full Text
• [23]Cai YY, Li ZZ, Fang ZJ: Living quality evaluation of the patients of Chronic obstructive pulmonary disease. Chin J Gen Pract 2004, 3(4):225-227.
• [24]CDC: Year of potential life lost before ages 65 and 85,United States,1989-1990. MMWR 1992, 18:313.
• [25]Kunik ME, Veazey C, Cully JA, Souchek J, Graham DP, Hopko D, Carter R, Sharafkhaneh A, Goepfert EJ, Wray N, Stanley MA: COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: a randomized controlled trial. Psychol Med 2008, 38(3):385-396.
• [26]Walker SL, Saltman DL, Colucci R, Martin L: Awareness of risk factors among persons at risk for lung cancer, chronic obstructive pulmonary disease and sleep apnea: A Canadian population-based study. Can Respir J 2010, 17(6):287-294.
• [27]Ning S, Wanzhen Y, Hong Z: Patient's perspective of chronic obstructive pulmonary disease in Yanqing County of Beijing. Chin J Tuberc Respir Dis 2008, 31(3):206-208.
• [28]Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van-Wel C, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555.
• [29]Zhou Y, Hu G, Wang D, Wang S, Wang Y, Liu Z, Hu J, Shi Z, Peng G, Liu S, Lu J, Zheng J, Wang J, Zhong N, Ran P: Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease(COPD)in Guangdong. China:cluster randomised controlled trial. BJM 2010, 341:c6387.
• [30]Tashkin DP: Long-acting anticholinergic use in chronic obstructive pulmonary disease:efficacy and safety. Curr Opin Pulm Med 2010, 16(2):97-105.
• [31]Miravitlles M: Prevention of exacerbations of COPD with pharmacotherapy. Eur Respir Rev 2010, 19(116):l19-l126.
• [32]Barr RG, Celli BR, Mannino DM, Petty T, Rennard SI, Sciurba FC, Stoller JK, Thomashow BM, Turino GM: Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009, 122(4):348-355.
• [33]Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkema-Ortiz J, Gardner DD, Wilkins RL: Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008, 3(3):371-384.
• [34]Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T: American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006, 173(12):1390-1413.
• [35]Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S: Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004, 125(6):2011-2020.
• [36]Xu F, Liang YQ, Shen HB, Xu YC: Years of potential life lost of chronic obstructive pulmonary diseases among residents in Nanjing from 1997 to 2005. Chin J Epidemiol 2007, 28(2):203-204.
• [37]Carrasco-Garrido P, de Miguel-Díez J, Rejas-Gutierrez J, Martín-Centeno A, Gobartt-Vázquez E, Hernandez-Barrera V, de Miguel AG, Jimenez-Garcia R: Characteristics of chronic obstructive pulmonary disease in Spain from a gender perspective. BMC Pulm Med 2009, 9:2. BioMed Central Full Text
• [38]Dalal AA, Christensen L, Liu F, Riedel AA: Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 2010, 5:341-349.